Table 3.
Proportion of patients experiencing a hemoglobin response at end of treatment and mean hemoglobin increase after 4 weeks of treatment by cohort
| Cohort | Responders Overall (EOT), n (%) | Mean (±SD) Hb Changes Overall, g/dl | Mean (±SD) Hb Changes by Category of Body Weight, g/dl | ||
|---|---|---|---|---|---|
| Lowest Tertile, ≤75.4 kg | Middle Tertile, 75.5–96.2 kg | Highest Tertile, ≥96.3 kg | |||
| A (n=23) | 19 (82.6)a | +1.71 (±0.21) | +1.80 (±0.98) | +1.72 (±1.10) | +1.65 (±1.10) |
| B (n=24) | 24 (100)a | +1.09 (±0.20) | +0.92 (±0.72) | +2.07 (±0.46) | +0.72 (±1.10) |
| C (n=23) | 21 (91.3)b | +0.57 (±0.21) | +0.90 (±0.45) | +0.40 (±0.62) | +0.60 (±0.80) |
| D (n=24) | 23 (95.8)b | +1.53 (±0.20) | +2.49 (±0.84) | +1.25 (±0.76) | +0.78 (±0.39) |
| E (n=24) | 23 (95.8)b | +0.77 (±0.20) | +0.61 (±0.88) | +0.95 (±0.83) | +0.77 (±0.75) |
| F (n=25) | 21 (84.0)b | +0.61 (±0.20) | +1.13 (±0.92) | +0.17 (±0.62) | +0.35 (±0.53) |
Hb, hemoglobin; EOT, end of treatment.
a
EOT 16 weeks.
b
EOT 24 weeks.